featured
2018 Top Stories in Diabetes: The ASCEND Study
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840-a1840.
- Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141.
- ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, StevensW, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi: 10.1056/NEJMoa1804988. Epub 2018 Aug 26. PubMed PMID: 30146931.
- Ridker PM. Should Aspirin Be Used for Primary Prevention in the Post-Statin Era? N Engl J Med. 2018 Oct 18;379(16):1572-1574. doi: 10.1056/NEJMe1812000.
Disclosure statements are available on the authors' profiles: